Cangrelor in ST-segment elevation myocardial infarction with high on-treatment platelet reactivity: a pilot randomized trial

Key Points

• This pilot trial aims to assess the effectiveness of cangrelor in reducing high platelet reactivity during ST-segment elevation myocardial infarction.
• Pilot randomized trial design
• Included patients with ST-segment elevation myocardial infarction and high platelet reactivity
• Utilized antiplatelet therapy with cangrelor
• Cangrelor significantly reduced platelet reactivity compared to the control group (exact metrics not stated)
• Patients receiving cangrelor showed improved clinical outcomes during treatment.
• Further studies are warranted to confirm these findings.